These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1439626)

  • 21. Multicenter study of the safety/efficacy of misoprostol in the prevention and treatment of NSAID-induced gastroduodenal lesions.
    Grazioli I; Avossa M; Bogliolo A; Broggini M; Carcassi A; Carcassi U; Cecconami L; Ligniere GC; Colombo B; Consoli G
    Clin Exp Rheumatol; 1993; 11(3):289-94. PubMed ID: 8353983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-efficiency of nonsteroidal anti-inflammatory drug prescribing in Zagreb, Croatia.
    Vukusić I; Stimac D; Culig J
    Coll Antropol; 2005 Jun; 29(1):143-7. PubMed ID: 16117313
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of NSAID-induced gastropathy: an economic decision analysis.
    Goldstein JL; Larson LR; Yamashita BD; Boyd MS
    Clin Ther; 1997; 19(6):1496-509; discussion 1424-5. PubMed ID: 9444455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diclofenac/misoprostol compared with diclofenac in the treatment of osteoarthritis of the knee or hip: a randomized, placebo controlled trial. Arthrotec Osteoarthritis Study Group.
    Bocanegra TS; Weaver AL; Tindall EA; Sikes DH; Ball JA; Wallemark CB; Geis GS; Fort JG
    J Rheumatol; 1998 Aug; 25(8):1602-11. PubMed ID: 9712107
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study.
    Brixner DI
    Med Interface; 1994 Nov; 7(11):145-50. PubMed ID: 10138701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An epidemiological approach to assess the economic burden of NSAID-induced gastrointestinal events in The Netherlands.
    Herings RM; Klungel OH
    Pharmacoeconomics; 2001; 19(6):655-65. PubMed ID: 11456213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.
    Chancellor JV; Hunsche E; de Cruz E; Sarasin FP
    Pharmacoeconomics; 2001; 19 Suppl 1():59-75. PubMed ID: 11280106
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology and pharmacoeconomic implications of non-steroidal anti-inflammatory drug-associated gastrointestinal toxicity.
    MacDonald TM
    Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():13-20; discussion 57-9. PubMed ID: 11276797
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preventing non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: are older strategies more cost-effective in the general population?
    Elliott RA; Hooper L; Payne K; Brown TJ; Roberts C; Symmons D
    Rheumatology (Oxford); 2006 May; 45(5):606-13. PubMed ID: 16368733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs.
    Dajani EZ; Agrawal NM
    Dig Dis; 1995 Jan; 13 Suppl 1():48-61. PubMed ID: 7697902
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Can we treat with modern antirheumatics? Costs of NSAID treatment].
    Bolten WW
    Pharm Unserer Zeit; 2002; 31(2):206-15. PubMed ID: 11977457
    [No Abstract]   [Full Text] [Related]  

  • 32. Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.
    de Groot NL; Spiegel BM; van Haalen HG; de Wit NJ; Siersema PD; van Oijen MG
    Value Health; 2013; 16(5):769-77. PubMed ID: 23947970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Is misoprostol effective in NSAID-induced gastrointestinal complications?].
    Stucki G; Sangha O; Michel BA
    Schweiz Med Wochenschr; 1996 Sep; 126(37):1573-8. PubMed ID: 8927962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.
    You JH; Lee KK; Chan TY; Lau WH; Chan FK
    Aliment Pharmacol Ther; 2002 Dec; 16(12):2089-96. PubMed ID: 12452942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gastrointestinal side effects of NSAIDs - pharmacoeconomic implications.
    Sheen CL; MacDonald TM
    Expert Opin Pharmacother; 2002 Mar; 3(3):265-9. PubMed ID: 11866677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arthrotec: the evidence speaks for itself.
    Morgan D
    Scand J Rheumatol Suppl; 1999; 109():13-8. PubMed ID: 10422542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ibuprofen versus other non-steroidal anti-inflammatory drugs: use in general practice and patient perception.
    Seager JM; Cullen DJ; Pearson G; Holmes S; Doherty M; Wilson JV; Garrud P; Garner S; Maynard A; Logan RF; Hawkey CJ
    Aliment Pharmacol Ther; 2000 Feb; 14(2):187-91. PubMed ID: 10651659
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and gastroduodenal safety of a fixed combination of diclofenac and misoprostol in the treatment of arthritis.
    McKenna F
    Br J Rheumatol; 1995 Apr; 34 Suppl 1():11-8. PubMed ID: 7780674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is misoprostol cost-effective in the prevention of nonsteroidal anti-inflammatory drug-induced gastropathy in patients with chronic arthritis? A review of conflicting economic evaluations.
    Stucki G; Johannesson M; Liang MH
    Arch Intern Med; 1994 Sep; 154(18):2020-5. PubMed ID: 8092907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.